The Annual JPMorgan Healthcare Conference Begins Today, And It’s Virtual For The Second Straight Year After The Companies raised concerns About the rising coronavirus cases.
Why this matters: Health care is as profitable as ever amid the global pandemic, and companies are eager to tell deep-pocketed power brokers why they should continue to pour more money into the industry and expect huge returns.
what to watch: Several companies that had record profits in 2021 are appearing at JPM, and a large portion of their pitches will revolve around what happens next as the highly permeable Omicron version escalates to the pandemic.
- Pfizer, BioNTech and Moderna have collected billions of dollars in sales from their mRNA vaccines, which have mostly gone to wealthy countries at the expense of low-income countries. Vaccine demand won’t subside, and Pfizer’s antiviral COVID pill could be an even bigger seller.
- The virtual phases will include Lonza, one of the most important COVID vaccine contract makers in the world, as well as troubled vaccine companies Johnson & Johnson, Novavax and Emergent Biosolutions.
- Demand for molecular and at-home antigen COVID tests will likely attract even greater interest from Abbott, Becton Dickinson, Quiddell, Quest Diagnostics, LabCorp, Thermo Fisher Scientific and Q Health.
- Buried on the conference agenda: Two Chinese vaccine makers, Sinovac Biotech and CanSino Biologics.
- Mergers and acquisitions are usually a core part of confab. Start of Pharma and Digital Health a. happened with Fist Of deal,
- 21 major hospitals are offering the system. Hospitals – which have used JPM as a measure of rising inpatient admissions and revenue growth for bondholders – will likely uncover shortages fueled by the latest outbreaks, and how those shortages affect their bottom lines.
Between the lines: Off-the-book meetings that are far from formal presentations are where purchase deals and strategic discussions take place. Many of them will also be pushed over video calls.
Bottom-line: The pandemic will again be front and center at JPM, but health care prices inevitably underpin all discussions.